AIM
CRL icon

Axiom Investment Management’s Charles River Laboratories CRL Stock Holding History

Axiom Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59K Buy
+7
New +$1.25K ﹤0.01% 446
2019
Q3 		– Sell
-1,696
Closed -$241K – 262
2019
Q2 		$241K Buy
+1,696
New +$230K 0.04% 325

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Axiom Investment Management's CRL Position: Q2 2026 in Review

Axiom Investment Management opened a new position in Charles River Laboratories (CRL) in Q2 2026: 7 shares worth $1.59K. The stake represents ﹤0.01% of the portfolio and ranks #446 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in CRL as recently as Q2 2019.

Axiom Investment Management first reported a position in CRL in Q2 2019 and has held it in 2 quarters since. The position peaked at $241K in Q2 2019. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Axiom Investment Management held 7 shares of Charles River Laboratories worth $1.59K as of Q2 2026.
  • Charles River Laboratories was a new Axiom Investment Management position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #446 holding.
  • Axiom Investment Management first reported a position in Charles River Laboratories in Q2 2019 and has held it in 2 quarters since.
  • Axiom Investment Management's Charles River Laboratories position peaked at $241K in Q2 2019.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.